Raj Chovatiya, MD, PhD: Takeaways from New Data on Vitiligo, Atopic Dermatitis, HS Treatments

(6:4)

Raj Chovatiya Gives Real-World Insights in Post-Approval Studies on Jak Inhibitors

(2:15)

Raj Chovatiya, MD, PhD: How Do Approved Eczema Treatments Compare?

(4:19)

Raj Chovatiya, MD - How effective is topical roflumilast at treating sensitive areas for psoriasis?

(49)

Raj Chovatiya, MD - What is the overall safety and tolerability profile for topical roflumilast?

(47)

Raj Chovatiya, MD - What is the mechanism of action of topical roflumilast?

(41)

Raj Chovatiya, MD, PhD

(1:1econd)

Raj Chovatiya, MD - Is topical roflumilast safe for long-term use?

(32)

Raj Chovatiya, MD - Can topical roflumilast be used for younger patients?

(30)

Raj Chovatiya, MD - What excites you most about the approval of topical roflumilast?

(27)

Raj Chovatiya, MD - Which patients may benefit the most from topical roflumilast?

(38)

Raj Chovatiya, MD - Can topical roflumilast replace topical corticosteroids?

(54)

Raj Chovatiya, MD - Do you augment oral and/or biologic therapy with a topical?

(44)

Raj Chovatiya, MD - How do you determine who is a candidate for a topical vs. an oral or biologic?

(44)

Raj Chovatiya Discussed Conditions Mimicking AD and Highlighted the Shift Toward Targeted Therapies

(4:2)

Raj Chovatiya, MD, PhD: Discussing the FDA Approval of Roflumilast for Atopic Dermatitis

(3:21)

Looking Back to Look Forward: Key Dermatology Updates in 2024

(4:)

Looking Back to Look Forward: Key Dermatology Updates in 2024

(4:)

Lebrikizumab for Atopic Dermatitis: 52-Week Efficacy Review with Dr. Raj Chovatiya I Clinical Trial

(3:29)